CRIS
- Curis, Inc.
()
Overview
Company Summary
Curis, Inc. (CRIS) is a biotechnology company primarily focused on developing and commercializing innovative and targeted drug candidates to treat cancer. The company's mission revolves around harnessing the power of precision medicine to create therapies that specifically target the underlying genetic and molecular drivers of cancer.
Curis employs a multi-faceted approach in its drug development efforts. They collaborate internally and with external partners to identify, validate, and advance potential drug candidates. These candidates are designed to address specific mechanisms and pathways involved in cancer's growth and survival. Curis leverages its expertise in cancer biology, advanced small molecule drug discovery, and antibody technologies to propel these candidates through preclinical and clinical phases of development.
One of Curis' notable drug candidates is CA-4948 (formerly PRT-060318), an orally available small molecule inhibitor of the enzyme serrated adenoma kinase (SAK) that is under investigation for the treatment of various hematologic malignancies. Additionally, the company is also working on fimepinostat (formerly CUDC-907), a dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes, which is being evaluated in clinical trials for the treatment of lymphoma and multiple myeloma.
Curis also collaborates with larger pharmaceutical companies, such as Aurigene Discovery Technologies Limited, to leverage their high-throughput screening and medicinal chemistry capabilities in the discovery and optimization of new drug candidates.
Overall, Curis, Inc. is dedicated to advancing innovative therapies that have the potential to improve the outcomes and quality of life for patients with cancer. Their approach focuses on targeting specific genetic and molecular abnormalities, with the ultimate aim of providing more effective and personalized treatment options.